AHIP lauds CMS decision on Alzheimer’s drug Aduhelm

Picture: Cecilie Arcurs/Getty Images

Insurance company advocacy group AHIP has praised the Centers for Medicare and Medicaid Expert services for its choice to have Medicare include an Alzheimer’s drug only for beneficiaries in clinical trials, agreeing with the federal company that far more proof is desired on Aduhelm and other drugs of its ilk.

In January, CMS released a proposed Countrywide Protection Willpower conclusion memorandum on the cure. The NCD would deal with Fda-permitted monoclonal antibodies that concentrate on amyloid for the remedy of Alzheimer’s disease by protection with proof advancement, indicating for Medicare recipients enrolled in qualifying scientific trials.

“AHIP supports accessibility to remedies that enhance a patient’s top quality of existence and ability to appreciate far more valued time with beloved ones,” the team wrote in a statement.

Dr. Lee Fleisher, CMS chief health care officer and director of the Heart for Medical Criteria and Good quality, said

Read More